0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Febrile Neutropenia Market Research Report 2024
Published Date: February 2024
|
Report Code: QYRE-Auto-37I8373
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Febrile Neutropenia Market Insights Forecast to 2028
BUY CHAPTERS

Global Febrile Neutropenia Market Research Report 2024

Code: QYRE-Auto-37I8373
Report
February 2024
Pages:75
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Febrile Neutropenia Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Febrile Neutropenia Market

Febrile Neutropenia Market

Febrile neutropenia, one of the most severe complications during cancer chemotherapy, is the development of fever with infection signals.
The global Febrile Neutropenia market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Febrile Neutropenia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Febrile Neutropenia.

Report Scope

The Febrile Neutropenia market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Febrile Neutropenia market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Febrile Neutropenia companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Febrile Neutropenia Market Report

Report Metric Details
Report Name Febrile Neutropenia Market
CAGR 5%
Segment by Type
  • Pegfilgrastim
  • Vancomycin Hydrochloride
  • Filgrastim Biosimilars
  • Pegfilgrastim Biosimilars
  • Others
Segment by Application
  • Hospitals
  • Clinics
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Xenetic Biosciences, Inc. (XBIO), Richter Gedeon Nyrt., Amgen Inc., Hospira, Inc., Eli Lilly and Company, USV Private Limited, Aequus BioPharma, Inc., Taiho Pharmaceutical Co., Ltd., BeyondSpring Inc.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Febrile Neutropenia companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Febrile Neutropenia Market report?

Ans: The main players in the Febrile Neutropenia Market are Xenetic Biosciences, Inc. (XBIO), Richter Gedeon Nyrt., Amgen Inc., Hospira, Inc., Eli Lilly and Company, USV Private Limited, Aequus BioPharma, Inc., Taiho Pharmaceutical Co., Ltd., BeyondSpring Inc.

What are the Application segmentation covered in the Febrile Neutropenia Market report?

Ans: The Applications covered in the Febrile Neutropenia Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Febrile Neutropenia Market report?

Ans: The Types covered in the Febrile Neutropenia Market report are Pegfilgrastim, Vancomycin Hydrochloride, Filgrastim Biosimilars, Pegfilgrastim Biosimilars, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Febrile Neutropenia Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Pegfilgrastim
1.2.3 Vancomycin Hydrochloride
1.2.4 Filgrastim Biosimilars
1.2.5 Pegfilgrastim Biosimilars
1.2.6 Others
1.3 Market by Application
1.3.1 Global Febrile Neutropenia Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Febrile Neutropenia Market Perspective (2019-2030)
2.2 Febrile Neutropenia Growth Trends by Region
2.2.1 Global Febrile Neutropenia Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Febrile Neutropenia Historic Market Size by Region (2019-2024)
2.2.3 Febrile Neutropenia Forecasted Market Size by Region (2025-2030)
2.3 Febrile Neutropenia Market Dynamics
2.3.1 Febrile Neutropenia Industry Trends
2.3.2 Febrile Neutropenia Market Drivers
2.3.3 Febrile Neutropenia Market Challenges
2.3.4 Febrile Neutropenia Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Febrile Neutropenia Players by Revenue
3.1.1 Global Top Febrile Neutropenia Players by Revenue (2019-2024)
3.1.2 Global Febrile Neutropenia Revenue Market Share by Players (2019-2024)
3.2 Global Febrile Neutropenia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Febrile Neutropenia Revenue
3.4 Global Febrile Neutropenia Market Concentration Ratio
3.4.1 Global Febrile Neutropenia Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Febrile Neutropenia Revenue in 2023
3.5 Febrile Neutropenia Key Players Head office and Area Served
3.6 Key Players Febrile Neutropenia Product Solution and Service
3.7 Date of Enter into Febrile Neutropenia Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Febrile Neutropenia Breakdown Data by Type
4.1 Global Febrile Neutropenia Historic Market Size by Type (2019-2024)
4.2 Global Febrile Neutropenia Forecasted Market Size by Type (2025-2030)
5 Febrile Neutropenia Breakdown Data by Application
5.1 Global Febrile Neutropenia Historic Market Size by Application (2019-2024)
5.2 Global Febrile Neutropenia Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Febrile Neutropenia Market Size (2019-2030)
6.2 North America Febrile Neutropenia Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Febrile Neutropenia Market Size by Country (2019-2024)
6.4 North America Febrile Neutropenia Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Febrile Neutropenia Market Size (2019-2030)
7.2 Europe Febrile Neutropenia Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Febrile Neutropenia Market Size by Country (2019-2024)
7.4 Europe Febrile Neutropenia Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Febrile Neutropenia Market Size (2019-2030)
8.2 Asia-Pacific Febrile Neutropenia Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Febrile Neutropenia Market Size by Region (2019-2024)
8.4 Asia-Pacific Febrile Neutropenia Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Febrile Neutropenia Market Size (2019-2030)
9.2 Latin America Febrile Neutropenia Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Febrile Neutropenia Market Size by Country (2019-2024)
9.4 Latin America Febrile Neutropenia Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Febrile Neutropenia Market Size (2019-2030)
10.2 Middle East & Africa Febrile Neutropenia Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Febrile Neutropenia Market Size by Country (2019-2024)
10.4 Middle East & Africa Febrile Neutropenia Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Xenetic Biosciences, Inc. (XBIO)
11.1.1 Xenetic Biosciences, Inc. (XBIO) Company Detail
11.1.2 Xenetic Biosciences, Inc. (XBIO) Business Overview
11.1.3 Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Introduction
11.1.4 Xenetic Biosciences, Inc. (XBIO) Revenue in Febrile Neutropenia Business (2019-2024)
11.1.5 Xenetic Biosciences, Inc. (XBIO) Recent Development
11.2 Richter Gedeon Nyrt.
11.2.1 Richter Gedeon Nyrt. Company Detail
11.2.2 Richter Gedeon Nyrt. Business Overview
11.2.3 Richter Gedeon Nyrt. Febrile Neutropenia Introduction
11.2.4 Richter Gedeon Nyrt. Revenue in Febrile Neutropenia Business (2019-2024)
11.2.5 Richter Gedeon Nyrt. Recent Development
11.3 Amgen Inc.
11.3.1 Amgen Inc. Company Detail
11.3.2 Amgen Inc. Business Overview
11.3.3 Amgen Inc. Febrile Neutropenia Introduction
11.3.4 Amgen Inc. Revenue in Febrile Neutropenia Business (2019-2024)
11.3.5 Amgen Inc. Recent Development
11.4 Hospira, Inc.
11.4.1 Hospira, Inc. Company Detail
11.4.2 Hospira, Inc. Business Overview
11.4.3 Hospira, Inc. Febrile Neutropenia Introduction
11.4.4 Hospira, Inc. Revenue in Febrile Neutropenia Business (2019-2024)
11.4.5 Hospira, Inc. Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Detail
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Febrile Neutropenia Introduction
11.5.4 Eli Lilly and Company Revenue in Febrile Neutropenia Business (2019-2024)
11.5.5 Eli Lilly and Company Recent Development
11.6 USV Private Limited
11.6.1 USV Private Limited Company Detail
11.6.2 USV Private Limited Business Overview
11.6.3 USV Private Limited Febrile Neutropenia Introduction
11.6.4 USV Private Limited Revenue in Febrile Neutropenia Business (2019-2024)
11.6.5 USV Private Limited Recent Development
11.7 Aequus BioPharma, Inc.
11.7.1 Aequus BioPharma, Inc. Company Detail
11.7.2 Aequus BioPharma, Inc. Business Overview
11.7.3 Aequus BioPharma, Inc. Febrile Neutropenia Introduction
11.7.4 Aequus BioPharma, Inc. Revenue in Febrile Neutropenia Business (2019-2024)
11.7.5 Aequus BioPharma, Inc. Recent Development
11.8 Taiho Pharmaceutical Co., Ltd.
11.8.1 Taiho Pharmaceutical Co., Ltd. Company Detail
11.8.2 Taiho Pharmaceutical Co., Ltd. Business Overview
11.8.3 Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Introduction
11.8.4 Taiho Pharmaceutical Co., Ltd. Revenue in Febrile Neutropenia Business (2019-2024)
11.8.5 Taiho Pharmaceutical Co., Ltd. Recent Development
11.9 BeyondSpring Inc.
11.9.1 BeyondSpring Inc. Company Detail
11.9.2 BeyondSpring Inc. Business Overview
11.9.3 BeyondSpring Inc. Febrile Neutropenia Introduction
11.9.4 BeyondSpring Inc. Revenue in Febrile Neutropenia Business (2019-2024)
11.9.5 BeyondSpring Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Febrile Neutropenia Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Pegfilgrastim
    Table 3. Key Players of Vancomycin Hydrochloride
    Table 4. Key Players of Filgrastim Biosimilars
    Table 5. Key Players of Pegfilgrastim Biosimilars
    Table 6. Key Players of Others
    Table 7. Global Febrile Neutropenia Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Febrile Neutropenia Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 9. Global Febrile Neutropenia Market Size by Region (2019-2024) & (US$ Million)
    Table 10. Global Febrile Neutropenia Market Share by Region (2019-2024)
    Table 11. Global Febrile Neutropenia Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 12. Global Febrile Neutropenia Market Share by Region (2025-2030)
    Table 13. Febrile Neutropenia Market Trends
    Table 14. Febrile Neutropenia Market Drivers
    Table 15. Febrile Neutropenia Market Challenges
    Table 16. Febrile Neutropenia Market Restraints
    Table 17. Global Febrile Neutropenia Revenue by Players (2019-2024) & (US$ Million)
    Table 18. Global Febrile Neutropenia Market Share by Players (2019-2024)
    Table 19. Global Top Febrile Neutropenia Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Febrile Neutropenia as of 2023)
    Table 20. Ranking of Global Top Febrile Neutropenia Companies by Revenue (US$ Million) in 2023
    Table 21. Global 5 Largest Players Market Share by Febrile Neutropenia Revenue (CR5 and HHI) & (2019-2024)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Febrile Neutropenia Product Solution and Service
    Table 24. Date of Enter into Febrile Neutropenia Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Febrile Neutropenia Market Size by Type (2019-2024) & (US$ Million)
    Table 27. Global Febrile Neutropenia Revenue Market Share by Type (2019-2024)
    Table 28. Global Febrile Neutropenia Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 29. Global Febrile Neutropenia Revenue Market Share by Type (2025-2030)
    Table 30. Global Febrile Neutropenia Market Size by Application (2019-2024) & (US$ Million)
    Table 31. Global Febrile Neutropenia Revenue Market Share by Application (2019-2024)
    Table 32. Global Febrile Neutropenia Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 33. Global Febrile Neutropenia Revenue Market Share by Application (2025-2030)
    Table 34. North America Febrile Neutropenia Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 35. North America Febrile Neutropenia Market Size by Country (2019-2024) & (US$ Million)
    Table 36. North America Febrile Neutropenia Market Size by Country (2025-2030) & (US$ Million)
    Table 37. Europe Febrile Neutropenia Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 38. Europe Febrile Neutropenia Market Size by Country (2019-2024) & (US$ Million)
    Table 39. Europe Febrile Neutropenia Market Size by Country (2025-2030) & (US$ Million)
    Table 40. Asia-Pacific Febrile Neutropenia Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 41. Asia-Pacific Febrile Neutropenia Market Size by Region (2019-2024) & (US$ Million)
    Table 42. Asia-Pacific Febrile Neutropenia Market Size by Region (2025-2030) & (US$ Million)
    Table 43. Latin America Febrile Neutropenia Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Latin America Febrile Neutropenia Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Latin America Febrile Neutropenia Market Size by Country (2025-2030) & (US$ Million)
    Table 46. Middle East & Africa Febrile Neutropenia Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 47. Middle East & Africa Febrile Neutropenia Market Size by Country (2019-2024) & (US$ Million)
    Table 48. Middle East & Africa Febrile Neutropenia Market Size by Country (2025-2030) & (US$ Million)
    Table 49. Xenetic Biosciences, Inc. (XBIO) Company Detail
    Table 50. Xenetic Biosciences, Inc. (XBIO) Business Overview
    Table 51. Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Product
    Table 52. Xenetic Biosciences, Inc. (XBIO) Revenue in Febrile Neutropenia Business (2019-2024) & (US$ Million)
    Table 53. Xenetic Biosciences, Inc. (XBIO) Recent Development
    Table 54. Richter Gedeon Nyrt. Company Detail
    Table 55. Richter Gedeon Nyrt. Business Overview
    Table 56. Richter Gedeon Nyrt. Febrile Neutropenia Product
    Table 57. Richter Gedeon Nyrt. Revenue in Febrile Neutropenia Business (2019-2024) & (US$ Million)
    Table 58. Richter Gedeon Nyrt. Recent Development
    Table 59. Amgen Inc. Company Detail
    Table 60. Amgen Inc. Business Overview
    Table 61. Amgen Inc. Febrile Neutropenia Product
    Table 62. Amgen Inc. Revenue in Febrile Neutropenia Business (2019-2024) & (US$ Million)
    Table 63. Amgen Inc. Recent Development
    Table 64. Hospira, Inc. Company Detail
    Table 65. Hospira, Inc. Business Overview
    Table 66. Hospira, Inc. Febrile Neutropenia Product
    Table 67. Hospira, Inc. Revenue in Febrile Neutropenia Business (2019-2024) & (US$ Million)
    Table 68. Hospira, Inc. Recent Development
    Table 69. Eli Lilly and Company Company Detail
    Table 70. Eli Lilly and Company Business Overview
    Table 71. Eli Lilly and Company Febrile Neutropenia Product
    Table 72. Eli Lilly and Company Revenue in Febrile Neutropenia Business (2019-2024) & (US$ Million)
    Table 73. Eli Lilly and Company Recent Development
    Table 74. USV Private Limited Company Detail
    Table 75. USV Private Limited Business Overview
    Table 76. USV Private Limited Febrile Neutropenia Product
    Table 77. USV Private Limited Revenue in Febrile Neutropenia Business (2019-2024) & (US$ Million)
    Table 78. USV Private Limited Recent Development
    Table 79. Aequus BioPharma, Inc. Company Detail
    Table 80. Aequus BioPharma, Inc. Business Overview
    Table 81. Aequus BioPharma, Inc. Febrile Neutropenia Product
    Table 82. Aequus BioPharma, Inc. Revenue in Febrile Neutropenia Business (2019-2024) & (US$ Million)
    Table 83. Aequus BioPharma, Inc. Recent Development
    Table 84. Taiho Pharmaceutical Co., Ltd. Company Detail
    Table 85. Taiho Pharmaceutical Co., Ltd. Business Overview
    Table 86. Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Product
    Table 87. Taiho Pharmaceutical Co., Ltd. Revenue in Febrile Neutropenia Business (2019-2024) & (US$ Million)
    Table 88. Taiho Pharmaceutical Co., Ltd. Recent Development
    Table 89. BeyondSpring Inc. Company Detail
    Table 90. BeyondSpring Inc. Business Overview
    Table 91. BeyondSpring Inc. Febrile Neutropenia Product
    Table 92. BeyondSpring Inc. Revenue in Febrile Neutropenia Business (2019-2024) & (US$ Million)
    Table 93. BeyondSpring Inc. Recent Development
    Table 94. Research Programs/Design for This Report
    Table 95. Key Data Information from Secondary Sources
    Table 96. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Febrile Neutropenia Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Febrile Neutropenia Market Share by Type: 2023 VS 2030
    Figure 3. Pegfilgrastim Features
    Figure 4. Vancomycin Hydrochloride Features
    Figure 5. Filgrastim Biosimilars Features
    Figure 6. Pegfilgrastim Biosimilars Features
    Figure 7. Others Features
    Figure 8. Global Febrile Neutropenia Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 9. Global Febrile Neutropenia Market Share by Application: 2023 VS 2030
    Figure 10. Hospitals Case Studies
    Figure 11. Clinics Case Studies
    Figure 12. Others Case Studies
    Figure 13. Febrile Neutropenia Report Years Considered
    Figure 14. Global Febrile Neutropenia Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 15. Global Febrile Neutropenia Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 16. Global Febrile Neutropenia Market Share by Region: 2023 VS 2030
    Figure 17. Global Febrile Neutropenia Market Share by Players in 2023
    Figure 18. Global Top Febrile Neutropenia Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Febrile Neutropenia as of 2023)
    Figure 19. The Top 10 and 5 Players Market Share by Febrile Neutropenia Revenue in 2023
    Figure 20. North America Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. North America Febrile Neutropenia Market Share by Country (2019-2030)
    Figure 22. United States Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Canada Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Europe Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Europe Febrile Neutropenia Market Share by Country (2019-2030)
    Figure 26. Germany Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. France Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. U.K. Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Italy Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Russia Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Nordic Countries Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Asia-Pacific Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Asia-Pacific Febrile Neutropenia Market Share by Region (2019-2030)
    Figure 34. China Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Japan Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. South Korea Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Southeast Asia Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. India Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Australia Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Latin America Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Latin America Febrile Neutropenia Market Share by Country (2019-2030)
    Figure 42. Mexico Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Brazil Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Middle East & Africa Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Middle East & Africa Febrile Neutropenia Market Share by Country (2019-2030)
    Figure 46. Turkey Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Saudi Arabia Febrile Neutropenia Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Xenetic Biosciences, Inc. (XBIO) Revenue Growth Rate in Febrile Neutropenia Business (2019-2024)
    Figure 49. Richter Gedeon Nyrt. Revenue Growth Rate in Febrile Neutropenia Business (2019-2024)
    Figure 50. Amgen Inc. Revenue Growth Rate in Febrile Neutropenia Business (2019-2024)
    Figure 51. Hospira, Inc. Revenue Growth Rate in Febrile Neutropenia Business (2019-2024)
    Figure 52. Eli Lilly and Company Revenue Growth Rate in Febrile Neutropenia Business (2019-2024)
    Figure 53. USV Private Limited Revenue Growth Rate in Febrile Neutropenia Business (2019-2024)
    Figure 54. Aequus BioPharma, Inc. Revenue Growth Rate in Febrile Neutropenia Business (2019-2024)
    Figure 55. Taiho Pharmaceutical Co., Ltd. Revenue Growth Rate in Febrile Neutropenia Business (2019-2024)
    Figure 56. BeyondSpring Inc. Revenue Growth Rate in Febrile Neutropenia Business (2019-2024)
    Figure 57. Bottom-up and Top-down Approaches for This Report
    Figure 58. Data Triangulation
    Figure 59. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS